Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Short term Debt (2016 - 2023)

Historic Short term Debt for Cartesian Therapeutics (RNAC) over the last 8 years, with Q4 2023 value amounting to $28.3 million.

  • Cartesian Therapeutics' Short term Debt rose 23396.65% to $28.3 million in Q4 2023 from the same period last year, while for Dec 2023 it was $28.3 million, marking a year-over-year increase of 23396.65%. This contributed to the annual value of $28.3 million for FY2023, which is 23396.65% up from last year.
  • As of Q4 2023, Cartesian Therapeutics' Short term Debt stood at $28.3 million, which was up 23396.65% from $10.2 million recorded in Q2 2023.
  • Cartesian Therapeutics' 5-year Short term Debt high stood at $28.3 million for Q4 2023, and its period low was $460000.0 during Q1 2021.
  • In the last 5 years, Cartesian Therapeutics' Short term Debt had a median value of $8.5 million in 2022 and averaged $11.1 million.
  • In the last 5 years, Cartesian Therapeutics' Short term Debt crashed by 9727.29% in 2021 and then skyrocketed by 136810.34% in 2023.
  • Over the past 5 years, Cartesian Therapeutics' Short term Debt (Quarter) stood at $18.9 million in 2019, then tumbled by 55.65% to $8.4 million in 2020, then decreased by 28.9% to $6.0 million in 2021, then surged by 42.19% to $8.5 million in 2022, then soared by 233.97% to $28.3 million in 2023.
  • Its Short term Debt stands at $28.3 million for Q4 2023, versus $10.2 million for Q2 2023 and $10.2 million for Q1 2023.